Xcout Intel
Olema Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Olema Pharmaceuticals, Inc. among biotechnology companies — ranked by similarity to what Olema Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Olema Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Olema Pharmaceuticals, Inc. at a glance
Olema Pharmaceuticals, Inc. is a biotechnology company headquartered in San Francisco, United States. It is publicly listed (OLMA) with a market capitalisation of $683.1M. Xcout tracks 73 named people at Olema Pharmaceuticals, Inc., including Sean Bohen (President, Chief Executive Officer & Director). Xcout recorded 45 job postings from Olema Pharmaceuticals, Inc. in the last 90 days.
Olema Pharmaceuticals, Inc. leadership
- Sean BohenPresident, Chief Executive Officer & Director
- Sean P. Bohen, M.D., Ph.D.President and CEO
- Jason O'ByrneCFO, Principal Financial Officer & Accounting Officer
- Naseem ZojwallaChief Medical Officer
- Shawnte MitchellChief Legal Officer & Corporate Secretary
- David C. MylesChief Scientific Officer
67 more named people on record for Olema Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Olema Pharmaceuticals, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $87.4M | 8 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Olema Pharmaceuticals, Inc.
Xcout recorded 45 job postings from Olema Pharmaceuticals, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Olema Pharmaceuticals, Inc.'s hiring signals →
Top 12 Olema Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Olema Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Similar biotechnology company
Asieris Pharmaceuticals is a global innovative biopharmaceutical company founded in March 2010 that specializes in the development of treatments for genitourinary tumors and women's health.
Similar biotechnology company
Oriva Therapeutics is a biotechnology and pharmaceutical company headquartered in Barcelona, Spain. The venture is dedicated to advancing innovative and disease-modifying approaches to improve clinical outcomes for chronic women's health conditions.
Pharmaceuticals
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Healthtech
Oviva Therapeutics is a biotechnology research subsidiary headquartered in New York, NY, focused on women's health. The company develops novel therapeutics designed to target ovarian function and extend healthspan.
Biotech
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Biotech
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Similar biotechnology company
Cybrexa Therapeutics is a clinical-stage oncology biotechnology company that develops tumor-targeting peptide-drug conjugates (PDCs) for cancer patients. Its proprietary alphalex technology uses a pH-driven approach for antigen-independent, intracellular delivery of anti-cancer agents directly to tumors and metastases.
Similar biotechnology company
Opna Bio is a clinical-stage biopharmaceutical company that discovers and develops novel oncology therapeutics targeting key regulators of cancer. Its pipeline includes epigenetic inhibitors such as OPN-6602 for multiple myeloma and zavabresib for myelofibrosis.
Similar biotechnology company
St. James Therapeutics is a clinical-stage biopharmaceutical company that develops specialized topical skincare products to treat chemotherapy-induced side effects, specifically hand-foot syndrome. The company serves cancer patients by creating science-backed solutions designed to make cancer treatment more tolerable.
Biotech
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Olema Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Olema Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →